Related Experiment Videos

[Long-term course of 6 boys with congenital nephrogenic diabetes insipidus]

R Kaulitz1, J Brodehl

  • 1Medizinische Hochschule Hannover, Kinderklinik.

Klinische Padiatrie
|November 1, 1989
PubMed

Insights

Congenital nephrogenic diabetes insipidus (cNDI) in boys can be effectively treated with hydrochlorothiazide and indomethacin. This combination therapy promotes normal growth and psychointellectual development in affected children.

Area of Science:

  • Pediatric Nephrology
  • Endocrinology
  • Genetics

Background:

  • Congenital nephrogenic diabetes insipidus (cNDI) is a rare genetic disorder affecting kidney function.
  • Early diagnosis and management are crucial for preventing severe complications like hypernatremia and dehydration.

Observation:

  • Six boys diagnosed with cNDI between 3 months and 10 years of age presented with polyuria and hypernatremia.
  • Symptoms of cNDI manifested within the first few weeks of life, confirmed by low urinary osmolality and lack of response to vasopressin.

Findings:

  • Hydrochlorothiazide monotherapy reduced urinary volume by 26-44%, resolving hypernatremia and enabling normal thriving.
  • Addition of indomethacin further decreased urinary volume by 50-60% in cases of increased polyuria.
  • The combination of hydrochlorothiazide and indomethacin was well-tolerated and effective in managing cNDI.

Implications:

  • Combined hydrochlorothiazide and indomethacin treatment is a necessary and effective strategy for cNDI, particularly in early childhood.
  • This therapeutic approach supports normal physical growth and psychointellectual development in children with cNDI.
  • Further research into long-term outcomes and optimal dosing strategies for cNDI treatment is warranted.

Related Concept Videos